| 21.44 0.24 (1.13%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.83 | 1-year : | 28.23 |
| Resists | First : | 22.97 | Second : | 24.17 |
| Pivot price | 21.84  |
|||
| Supports | First : | 21.04 | Second : | 17.51 |
| MAs | MA(5) : | 21.38 |
MA(20) : | 22.06 |
| MA(100) : | 22.59 |
MA(250) : | 21.01 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 13.8 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 25.14 | Low : | 16.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INVA ] has closed above bottom band by 23.9%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.52 - 21.64 | 21.64 - 21.75 |
| Low: | 20.97 - 21.13 | 21.13 - 21.27 |
| Close: | 21.21 - 21.44 | 21.44 - 21.65 |
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Fri, 24 Jul 2026
INVA|Innoviva Inc|Price:21.440|Chg%:+0.240 - TradingKey
Tue, 21 Jul 2026
Innoviva, Inc. (INVA) Stock Analysis: Exploring a Potential 66.82% Upside in the Healthcare Sector - DirectorsTalk Interviews
Sun, 19 Jul 2026
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing - Stock Traders Daily
Sat, 27 Jun 2026
INVA Forecast — Price Target — Prediction for 2027 - TradingView
Sat, 27 Jun 2026
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership - Sahm
Thu, 25 Jun 2026
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 107.8 (%) |
| Shares Short | 6,650 (K) |
| Shares Short P.Month | 5,860 (K) |
| EPS | 6.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.18 |
| Profit Margin | 119.8 % |
| Operating Margin | 40.1 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 50.7 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 4.22 |
| Sales Per Share | 5.69 |
| EBITDA (p.s.) | 2.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 184 (M) |
| Levered Free Cash Flow | 105 (M) |
| PE Ratio | 3.41 |
| PEG Ratio | 0.3 |
| Price to Book value | 1.17 |
| Price to Sales | 3.76 |
| Price to Cash Flow | 8.61 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 1.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|